A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity

• Published in: Cancer science 2005-09, Vol.96 (9), p.614-619
• Main Authors: Aoyagi, Yoshimi, Masuko, Norio, Ohkubo, Shuichi, Kitade, Makoto, Nagai, Kentaro, Okazaki, Shinji, Wierzba, Konstanty, Terada, Tadafumi, Sugimoto, Yoshikazu, Yamada, Yuji
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; cdc25 Phosphatases - antagonists & inhibitors; cdc25 Phosphatases - metabolism; Cell Cycle Proteins - physiology; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; G1 Phase - drug effects; G1 Phase - physiology; Humans; Kinetics; Lung Neoplasms - pathology; Medical sciences; Original; Phosphorylation; Pyrazoles - pharmacology; Retinoblastoma Protein - metabolism; Tumor Cells, Cultured; Tumors
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/j.1349-7006.2005.00086.x

The Cdc25 dual‐specificity phosphatases are key regulators of cell cycle progression through activation of cyclin‐dependent kinases (Cdk). Three homologs exist in humans: Cdc25A, Cdc25B, and Cdc25C. Cdc25A and Cdc25B have oncogenic properties and are overexpressed in some types of tumors. Compounds that inhibit Cdc25 dual‐specificity phosphatase activity might thus be potent anticancer agents. We screened several hundred compounds in a library using an in vitro phosphatase assay, with colorimetric measurement of the conversion of p‐nitrophenyl phosphate (pNPP) to p‐nitrophenol by the catalytic domain of recombinant human Cdc25, and discovered TPY‐835, which inhibits Cdc25A and Cdc25B activity (IC50 = 5.1 and 5.7 µM, respectively). TPY‐835 had mixed inhibition kinetics for Cdc25A and Cdc25B. TPY‐835 caused cell cycle arrest in the G1 phase in human lung cancer cells (A549 and SBC‐5) but not cell cycle arrest in the G2/M phase. After treatment with TPY‐835, the activation of Cdk2 was suppressed and phosphorylation of the retinoblastoma (Rb) protein was decreased in SBC‐5 cells. In addition, TPY‐835 induced an increase of the sub‐G1 phase cell population after 48–72 h treatment. The growth inhibitory effects of TPY‐835 against cisplatin (CDDP)‐, camptothecin‐ and 5‐FU‐resistant cell lines are comparable to the growth inhibitory effect on their parental lines, thus indicating that TPY‐835 did not show cross‐resistance to these cell lines. These results suggest that TPY‐835 is a promising candidate for constructing a novel class of antitumor agents that can control the cell cycle progression of cancer cells. (Cancer Sci 2005; 96: 614–619)